#1 Clinical Trials Search in Europe

LY3848575

Clinical trials are investigating LY3848575 in people with painful distal sensory polyneuropathy, a type of nerve damage that can cause pain. The main goal is to see whether LY3848575 can reduce pain better than placebo and to measure safety and other study results.

Table of Contents

Trial overview

The available study of LY3848575 was an interventional trial, which means researchers gave a study treatment and then measured the results.[1] It was a Phase 2 trial and is listed as completed.[1] The trial included 450 participants and studied pain in people with painful distal sensory polyneuropathy.[1]

Who was studied

The study focused on participants with neuropathic pain and distal sensory polyneuropathy.[1] Neuropathic pain is pain caused by nerve damage or nerve problems, and distal sensory polyneuropathy is a nerve condition that often affects the hands or feet and can cause pain.[1] The source data does not give more details about age, sex, or other entry rules.[1]

What the trial measured

The main outcome was the Mean Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS).[1] Baseline means the starting point before treatment, and the API-NRS is a pain score used to track how pain changes over time.[1] The brief summary says the study aimed to show that at least one dose of LY3848575 was better than placebo for pain intensity.[1]

Trial design and treatment comparison

Participants were assigned to LY3848575 given by subcutaneous injection or to a placebo made to match LY3848575.[1] A placebo is a look-alike treatment that does not contain the active study drug and helps researchers compare results fairly.[1] This design helps show whether any pain improvement is linked to LY3848575 rather than to chance or expectations.[1]

What the trial aimed to show

The study aimed to test whether LY3848575 could reduce pain better than placebo in people with painful distal sensory polyneuropathy.[1] This is an important question because the condition can cause long-lasting nerve pain that affects daily life.[1] Because the trial is completed, the main research question is whether the measured pain scores showed a meaningful difference between the study treatment and placebo.[1]

Trial ID Phase Condition studied Status Enrollment
2024-513435-24-01 Phase 2 Neuropathic Pain; Distal Sensory Polyneuropathy Completed 450

FAQ

  • What is LY3848575 being studied for in clinical trials? It is being studied for pain caused by distal sensory polyneuropathy. The trial is looking at whether it can lower average pain more than placebo.
  • Who can take part in the LY3848575 trial? The trial includes participants with painful distal sensory polyneuropathy. The study data does not give more detail about age or other entry rules.
  • What phase is the LY3848575 trial? This study is a Phase 2 trial. Phase 2 trials usually look more closely at whether a treatment may work and continue to collect safety data.
  • What does placebo mean in this trial? Placebo means a treatment made to look like LY3848575 but without the active study drug. It helps researchers compare results fairly.
  • What outcome is the trial measuring? The main outcome is the change in average pain intensity from the start of the study. It is measured with the Average Pain Intensity Numeric Rating Scale, or API-NRS, which is a pain score.

Ongoing Clinical Trials on LY3848575

  • Study on LY3848575 for Reducing Pain in Patients with Distal Sensory Polyneuropathy

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Poland

Glossary

  • Clinical trial: A research study in people that tests whether a treatment is safe, helpful, or both.
  • Phase 2: A mid-stage trial that looks more closely at whether a treatment may work and continues safety checks.
  • Placebo: A look-alike treatment that does not contain the active study drug. It is used for comparison.
  • Interventional study: A study where researchers give a treatment or other intervention and then measure the results.
  • Distal sensory polyneuropathy: A condition that affects nerves, usually in the hands or feet, and can cause pain or other feeling problems.
  • Neuropathic pain: Pain caused by nerve damage or nerve problems.
  • Subcutaneous injection: An injection given under the skin.
  • Enrollment: The number of people planned or included in a study.
  • Primary outcome: The main result the researchers want to measure in the trial.
  • API-NRS: Average Pain Intensity Numeric Rating Scale, a number scale used to measure pain level.

References

  1. https://clinicaltrials.gov/study/2024-513435-24-01